Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.72 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.72 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.72 |
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.53 |
| ▸ | HPGD | P15428 | 4/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.53 |
| ▸ | TSHR | P16473 | 3/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.53 |
| ▸ | HTT | P42858 | 2/20 | 0.53 |
| ▸ | USP2 | O75604 | 1/20 | 0.53 |
| ▸ | ATM | Q13315 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.49 |
| ▸ | MAPT | P10636 | 3/20 | 0.49 |
| ▸ | RAB9A | P51151 | 3/20 | 0.49 |
| ▸ | NPC1 | O15118 | 2/20 | 0.49 |
| ▸ | ACACA | Q13085 | 1/20 | 0.49 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.48 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.47 |
| ▸ | PDE4A | P27815 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21058420 | 0.86 | MEN1 (0.55) | MEN1KMT2AL3MBTL1KDM4EALDH1A1 | |
| SCHEMBL21058771 | 0.86 | MEN1 (0.55) | MEN1KMT2AL3MBTL1KDM4EALDH1A1 | |
| SCHEMBL4502579 | 0.85 | KDM4E (0.68) | MEN1KMT2AL3MBTL1KDM4EALDH1A1 | |
| SCHEMBL10686590 | 0.85 | MEN1 (0.57) | MEN1KMT2AL3MBTL1KDM4EALDH1A1 | |
| SCHEMBL12408679 | 0.85 | MEN1 (0.70) | MEN1KMT2AL3MBTL1KDM4EALDH1A1 | |
| SCHEMBL6749872 | 0.84 | HSP90AA1 (0.61) | MEN1KMT2AL3MBTL1KDM4EALDH1A1 | |
| SCHEMBL4489879 | 0.81 | MEN1 (0.54) | MEN1KMT2AL3MBTL1KDM4EALDH1A1 | |
| SCHEMBL6504726 | 0.80 | MEN1 (0.63) | MEN1KMT2AL3MBTL1KDM4EALDH1A1 | |
| SCHEMBL3451541 | 0.79 | KDM4E (0.67) | MEN1KMT2AL3MBTL1KDM4EALDH1A1 | |
| SCHEMBL4504428 | 0.79 | KMT2A (0.67) | MEN1KMT2AL3MBTL1KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130072477-A1 | TREATMENT OF PARKINSON'S DISEASE AND ENHANCEMENT OF DOPAMINE SIGNAL USING PDE 10 INHIBITOR | MITSUBISHI TANABE PHARMA COPORATION (JP) | 2013-03-21 | — | — | US | disclosed |
| EP-2342191-B1 | AROMATIC NITROGEN-CONTAINING 6-MEMBERED RING COMPOUNDS AND THEIR USE | MITSUBISHI TANABE PHARMA CORP (JP) | 2013-03-20 | — | — | EP | disclosed |
| US-8338420-B1 | Treatment of Parkinson's disease and enhancement of dopamine signal using PDE 10 inhibitor | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-12-25 | — | — | US | disclosed |
| EP-2342191-A1 | AROMATIC NITROGEN-CONTAINING 6-MEMBERED RING COMPOUNDS AND THEIR USE | Mitsubishi Tanabe Pharma Corporation (JP) | 2011-07-13 | — | — | EP | disclosed |
| US-20110166135-A1 | AROMATIC NITROGEN-CONTAINING 6-MEMBERED RING COMPOUNDS AND THEIR USE | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-07-07 | — | — | US | disclosed |
| US-20110166135-A1 | AROMATIC NITROGEN-CONTAINING 6-MEMBERED RING COMPOUNDS AND THEIR USE | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-07-07 | — | — | US | disclosed |
| US-20110166135-A1 | AROMATIC NITROGEN-CONTAINING 6-MEMBERED RING COMPOUNDS AND THEIR USE | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-07-07 | — | — | US | disclosed |
| WO-2010030027-A1 | AROMATIC NITROGEN-CONTAINING 6-MEMBERED RING COMPOUNDS AND THEIR USE | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-03-18 | — | — | WO | disclosed |
| US-6911443-B2 | Imidazopyrimidine derivatives and triazolopyrimidine derivatives | BAYER AKTIENGESELLSCHAFT (DE) | 2005-06-28 | — | — | US | disclosed |
| EP-1278750-B1 | IMIDAZOPYRIMIDINE DERIVATIVES AND TRIAZOLOPYRIMIDINE DERIVATIVES | BAYER HEALTHCARE AG (DE) | 2004-08-04 | — | — | EP | disclosed |
| US-20040054179-A1 | Imidazopyrimidine derivatives and triazolopyrimidine derivatives | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2004-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040054179-A1 | Imidazopyrimidine derivatives and triazolopyrimidine derivatives | XRCC6, XRN2, HRH2 | MEN1 3675/4885KMT2A 1132/4885L3MBTL1 1969/4885 |
| US-20110166135-A1 | AROMATIC NITROGEN-CONTAINING 6-MEMBERED RING COMPOUNDS AND THEIR USE | PDE10A, PDE3A, PDE3B | MEN1 1655/4885KMT2A 2102/4885L3MBTL1 4808/4885 |
| US-20130072477-A1 | TREATMENT OF PARKINSON'S DISEASE AND ENHANCEMENT OF DOPAMINE SIGNAL USING PDE 10 INHIBITOR | PDE3A, PDE2A, PDE5A | MEN1 4225/4885KMT2A 2937/4885L3MBTL1 4514/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.